Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sumatriptan

FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sumatriptan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
FDA pharmacologic class
Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sumatriptan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

    NCT00434083 · start 2004-07

    Registered record
    Registry ID
    NCT00434083
    Conditions
    Migraine Headaches
    Interventions
    sumatriptan; naproxen sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-01
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headaches
    Interventionsumatriptan; naproxen sodium
    PhasePhase 3
    Registry statusCompleted

  • Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions

    NCT00847405 · start 2003-03

    Registered record
    Registry ID
    NCT00847405
    Conditions
    Healthy
    Interventions
    Sumatriptan Succinate; Imitrex®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-03
    Completion
    2003-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSumatriptan Succinate; Imitrex®
    PhasePhase 1
    Registry statusCompleted

  • Sumatriptan and Naratriptan Pregnancy Registry

    NCT01059604 · start 2001-12

    Registered record
    Registry ID
    NCT01059604
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan; Naratriptan; Sumatriptan-naproxen combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-12
    Completion
    2013-04
    Enrolment
    868

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan; Naratriptan; Sumatriptan-naproxen combination
    PhaseNot recorded
    Registry statusCompleted

  • Drug Use Investigation for IMIGRAN Tablet

    NCT01376141 · start 2001-09

    Registered record
    Registry ID
    NCT01376141
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-09
    Completion
    2005-11
    Enrolment
    3,571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan
    PhaseNot recorded
    Registry statusCompleted

  • MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

    NCT00897104 · start 1995-08

    Registered record
    Registry ID
    NCT00897104
    Conditions
    Migraine Headache
    Interventions
    rizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-08
    Completion
    1996-09
    Enrolment
    933

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    Interventionrizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: Placebo
    PhasePhase 3
    Registry statusCompleted